Press Release Oct 23 2024
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited announced that its Typhoid Vi Conjugate Vaccine, ZyVac TCV, has received prequalification from the World Health Organisation. This prequalification allows ZyVac TCV to be eligible for purchase by United Nations procurement agencies. The vaccine is developed to immunize against Salmonella typhi infection and is manufactured at Zydus Biotech Park in Ahmedabad.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Oct 17 2024
- Press Release Oct 14 2024
- Press Release Oct 10 2024
- Press Release Oct 02 2024
- Press Release Oct 01 2024
Later from Zydus Lifesciences
- Press Release Nov 12 2024
- Press Release Dec 19 2024
- Zydus Lifesciences Limited Press Release Jan 07 2025
- Press Release Jan 18 2025
- Press Release Jan 22 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences